AstraZeneca (NASDAQ:AZN) Stock Acquired Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of AstraZeneca PLC (NASDAQ:AZN). In a filing disclosed on December 15th, the Representative disclosed that they had bought between $1,001 and $15,000 in AstraZeneca stock on November 19th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Spotify Technology (NYSE:SPOT) on 11/26/2025.
• Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 11/26/2025.
• Purchased $1,001 – $15,000 in shares of First Watch Restaurant Group (NASDAQ:FWRG) on 11/26/2025.
• Purchased $1,001 – $15,000 in shares of TKO Group (NYSE:TKO) on 11/26/2025.
• Sold $1,001 – $15,000 in shares of RBC Bearings (NYSE:RBC) on 11/24/2025.
• Sold $1,001 – $15,000 in shares of Stifel Financial (NYSE:SF) on 11/24/2025.
• Purchased $1,001 – $15,000 in shares of Logan Energy (CVE:LGN) on 11/24/2025.
• Sold $1,001 – $15,000 in shares of Primoris Services (NASDAQ:PRIM) on 11/24/2025.
• Purchased $15,001 – $50,000 in shares of LandBridge (NYSE:LB) on 11/21/2025.
• Purchased $50,001 – $100,000 in shares of LandBridge (NYSE:LB) on 11/20/2025.

AstraZeneca Stock Up 0.8%

AZN traded up $0.75 during midday trading on Friday, reaching $91.36. 8,372,783 shares of the company were exchanged, compared to its average volume of 5,218,068. The company has a market cap of $283.35 billion, a price-to-earnings ratio of 30.35, a price-to-earnings-growth ratio of 1.66 and a beta of 0.32. AstraZeneca PLC has a one year low of $61.24 and a one year high of $94.01. The company’s fifty day moving average price is $87.46 and its 200 day moving average price is $79.65. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.69 and a current ratio of 0.88.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings results on Thursday, November 6th. The company reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.14 by $0.05. The business had revenue of $15.19 billion during the quarter, compared to the consensus estimate of $14.75 billion. AstraZeneca had a return on equity of 32.89% and a net margin of 16.17%.AstraZeneca’s revenue was up 12.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.08 earnings per share. As a group, analysts expect that AstraZeneca PLC will post 4.51 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on AZN. Weiss Ratings reaffirmed a “buy (b)” rating on shares of AstraZeneca in a research report on Wednesday, October 8th. Cowen reaffirmed a “buy” rating on shares of AstraZeneca in a research report on Tuesday, December 9th. Jefferies Financial Group initiated coverage on AstraZeneca in a research note on Monday, October 27th. They set a “buy” rating on the stock. Guggenheim restated a “buy” rating on shares of AstraZeneca in a research report on Wednesday, December 3rd. Finally, HSBC restated a “buy” rating and set a $108.00 price objective on shares of AstraZeneca in a report on Wednesday, December 10th. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $95.75.

Hedge Funds Weigh In On AstraZeneca

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Primecap Management Co. CA grew its position in shares of AstraZeneca by 1.3% during the 2nd quarter. Primecap Management Co. CA now owns 41,200,091 shares of the company’s stock valued at $2,879,062,000 after purchasing an additional 538,606 shares in the last quarter. Bank of America Corp DE raised its position in shares of AstraZeneca by 4.7% in the third quarter. Bank of America Corp DE now owns 32,633,139 shares of the company’s stock worth $2,503,614,000 after buying an additional 1,461,786 shares in the last quarter. Franklin Resources Inc. boosted its stake in AstraZeneca by 0.9% during the second quarter. Franklin Resources Inc. now owns 21,298,394 shares of the company’s stock valued at $1,488,332,000 after buying an additional 196,401 shares during the period. Fisher Asset Management LLC grew its position in AstraZeneca by 2.3% during the third quarter. Fisher Asset Management LLC now owns 21,162,724 shares of the company’s stock worth $1,623,604,000 after buying an additional 466,745 shares in the last quarter. Finally, Jennison Associates LLC grew its position in AstraZeneca by 15.2% during the second quarter. Jennison Associates LLC now owns 12,167,365 shares of the company’s stock worth $850,255,000 after buying an additional 1,605,133 shares in the last quarter. Institutional investors own 20.35% of the company’s stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

AstraZeneca Company Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.